OPNT News and Press, Opiant Pharmaceuticals Inc. From 11/12/20

Opiant Pharmaceuticals, Inc. (OPNT) Q3 2020 Earnings Conference Call November 12, 2020 4:30 PM ET Company Participants Ben Atkins - VP, Communications & IR Roger Crystal - President, Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brandon Folke...

Opiant Pharmaceuticals (OPNT): Q3 GAAP EPS of $0.15 beats by $0.36.Revenue of $9.11M (-55.9% Y/Y) beats by $1.35M.Press Release For further details see: Opiant Pharmaceuticals EPS beats by $0.36, beats on revenue

SANTA MONICA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended Septe...

SANTA MONICA, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Cryst...

Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene , with Apta r's FD A-approved Unit Dose System delivery device R einforces Opiant’s continued commitment to innovative over...

SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its third quarter 2020 financial r...

SANTA MONICA, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Cryst...

Opiant Pharmaceuticals, Inc. (OPNT) Q2 2020 Earnings Conference Call August 06, 2020, 16:30 ET Company Participants Ben Atkins - VP, Communications & IR Roger Crystal - President, CEO & Director David O'Toole - CFO Conference Call Participants Brandon Folkes - Canto...

Opiant Pharmaceuticals (NASDAQ: OPNT ) : Q2 GAAP EPS of -$0.05 beats by $0.19 . More news on: Opiant Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SANTA MONICA, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended June ...